Earlier during the day, Becton, Dickinson and Company (BD) declared that it has completed acquisition of a Swedish company, Carmel Pharma, AB.
Carmel manufactures a closed-system drug transfer device known as the PhaSeal® System intended for the secure management of harmful drugs packaged in vials. With the acquisition of Carmel, BD will broaden the scope of its healthcare worker safety procedures and emphasize on reducing hazardous drug exposure.
Alberto Mas, President, BD Medical – Medical Surgical Systems said, “Carmel Pharma is a leader in an early-stage market with significant long-term growth potential. We’re excited to begin moving forward to address the critically important issue of hazardous drug exposure to healthcare providers by raising awareness, driving advocacy efforts, developing pharmacy and nursing relationships, and expanding market reach around the world for this product category.”
Alexandre Conroy, President, BD – Western Europe said, “We are pleased to welcome this new platform and these new associates to BD. Healthcare worker safety is an important focus for BD in Europe, and globally. Through this acquisition, BD will be able to provide an enhanced suite of safety products to our customers.”